Novavax reported $-343419000 in EBITDA for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Adma Biologics ADMA:US $ -14.26M 0.39M
Agenus AGEN:US $ -64.67M 25.03M
Astrazeneca AZN:US $ 2149M 322M
AstraZeneca AZN:LN 2149M 322M
BioSpecifics Technologies BSTC:US 6.54 6.76
Dynavax Technologies DVAX:US $ 10.78M 19.34M
Genocea Biosciences GNCA:US $ -14.18M 2.13M
GlaxoSmithKline GSK:LN 2626M 584M
Kindred Biosciences KIN:US $ -7.33M 0.63M
Mannkind MNKD:US $ -8.02M 1.36M
Minerva Neurosciences NERV:US $ -8.96M 1.46M
Moderna Inc MRNA:US 3.13B 1.85B
Novartis NVS:US $ 4772M 423M
Novavax NVAX:US $ -343.42M 137.1M
Pain Therapeutics PTIE:US $ -5.13M 1.6M
Peregrine Pharmaceuticals PPHM:US $ 7.94M 3.85M
Pfizer PFE:US $ 7593M 610M
Sarepta Therapeutics SRPT:US $ -159.13M 26.19M